SCHEMBL27185229

SCHEMBL27185229

CNc1ccc2c(OC)cc(C(=O)OC)cc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACA Q13085 1/20 0.46
KDM4E B2RXH2 3/20 0.46
PDE3B Q13370 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.43
CYP3A4 P08684 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SLC2A1 P11166 1/20 0.42
ALOX15 P16050 1/20 0.41
CSNK2A1 P68400 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27185316 0.89 ALOX15 (0.48) ACACAPDE3BNPC1RAB9ASLC2A1
SCHEMBL27185326 0.84 KDM4E (0.60) KDM4EALDH1A1MAPTRAB9AALOX15
SCHEMBL24635160 0.77 HTT (0.49) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL25981002 0.77 MAPT (0.47) KDM4EPDE3BALDH1A1MAPTALOX15
SCHEMBL27077347 0.77 CSNK2A1 (0.52) KDM4EPDE3BALDH1A1MAPTNPC1
SCHEMBL21729783 0.77 KDM4E (0.55) KDM4EALDH1A1MAPTCYP3A4ALOX15
SCHEMBL27185238 0.75 SYK (0.55) KDM4EALDH1A1MAPTALOX15PDE4D
SCHEMBL25981004 0.73 ALDH1A1 (0.64) KDM4EALDH1A1MAPTALOX15CSNK2A1
SCHEMBL29893052 0.72 RAF1 (0.48) KDM4EALDH1A1MAPTCSNK2A1KMT2A
SCHEMBL1731139 0.72 ALOX15 (0.54) KDM4EMAPTALOX15CSNK2A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562017-A1 NOVEL ACC INHIBITORS Pfizer Inc. (US) 2025-06-04 EP disclosed
CN-120019059-A Novel ACC inhibitors 辉瑞公司 2025-05-16 CN disclosed
US-20240109915-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-04-04 US disclosed
WO-2024023727-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109915-A1 NOVEL ACC INHIBITORS CBR3, NAT1, ACACB ACACA 5/4885KDM4E 4784/4885PDE3B 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.